16 recruiting, 15 completed, 10 not yet recruiting, 4 terminated. 15 Phase 2, 6 Not applicable, 4 Early Phase 1, 4 Phase 3, 3 Phase 1.
Follow Membranous Nephropathy: new trials by email Literature Review of Membranous Nephropathy trials Research Report on Membranous Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Early PLA2R Status in Severe Anti-PLA2R-mediated Membranous Nephropathy and Long Term Kidney Outcome. Membranous Nephropathy, Major Adverse Kidney Events | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 250 | 2026-11-01 | 2026-11-12 | |
| Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays - Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced | Not applicable | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 12 | 2026-10-31 | 2026-09-10 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis | Not yet recruiting | Axiom Bioregistry | 5000 | 2026-10-18 | 2026-10-23 | |
| Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study IgA Nephropathy (IgAN), IgA Vasculitis | Recruiting | Pediatric Nephrology Research Consortium | 1000 | 2026-10-01 | 2026-11-12 | |
| Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial Obinutuzumab - Lupus Nephritis, Membranous Nephropathy | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 65 | 2026-09-02 | 2026-07-23 |
| Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy Membranous Nephropathy, Nephrotic Syndrome | Not yet recruiting | Assiut University | 128 | 2026-08-20 | 2026-09-02 | |
| Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy CD19 CAR-γδ T cell - Membranous Nephropathy, Lupus Nephritis (LN) | Early Phase 1 | Not yet recruiting | Air Force Military Medical University, China | 15 | 2026-05-01 | 2026-04-16 |
| Omics of Rituximab-resistance Multi-omics Analysis, Sample collection - Membranous Nephropathy | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 120 | 2026-04-01 | 2026-02-18 | |
| Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy Rituximab combined with cyclosporine, rituximab - Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 90 | 2026-01-21 | 2026-10-06 |
| Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy Flow-cytometry tetramer-based antigen-bait assay - Membranous Nephropathy | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 48 | 2025-09-22 | 2026-03-20 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis HLX79 10mg/kg/Placebo+HLX01, HLX79 20mg/kg/Placebo + HLX01, HLX79 30mg/kg/placebo+HLX01 - Membranous Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Shanghai Henlius Biotech | 24 | 2025-08-05 | 2025-11-18 |
| Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) RiTUXimab Injection - Membranous Nephropathy | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Nice | 120 | 2025-02-04 | 2026-06-22 |
| IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients IM19 chimeric antigen receptor T cell injection - IgA Nephropathy, Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Beijing Immunochina Medical Science & Technology Co., Ltd. | 12 | 2024-12-13 | 2024-11-26 |
| An Outcome Analysis of Primary Membranous Nephropathy Membranous Nephropathy | Recruiting | Mario Negri Institute for Pharmacological Research | 500 | 2024-11-29 | 2026-03-23 | |
| Circulating Factors in Nephrotic Syndrome Observation - Nephrotic Syndrome, Membranous Nephropathy | Not yet recruiting | Iain Bressendorff | 104 | 2024-04-01 | 2024-03-19 | |
| Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Peginterferon Alfa-2A 180 MCG/ML Injectable Solution - Membranous Nephropathy | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2023-09-14 | 2026-06-18 |
| Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome Rituximab (MABTHERA® or RITUXAN®)., Corticosteroids (CS) - Membranous Nephropathy, Minimal Change Disease (MCD) | Completed | University Hospital, Ioannina | 40 | 2023-06-01 | 2026-07-14 | |
| Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced | Completed | Istanbul University | 44 | 2023-06-01 | 2026-07-13 |
Showing 20 of 47. Sign in to see all of them.
Glomerulonephritis, Membranous (47) · Nephrotic Syndrome (12) · Glomerulonephritis, IGA (11) · Glomerulosclerosis, Focal Segmental (10) · Nephrosis, Lipoid (9) · Lupus Nephritis (7) · Glomerulonephritis (5) · Kidney Diseases (4) · Macular dystrophy, corneal type 1 (4) · Nephritis, Hereditary (4) · Proteinuria (4) · Glomerulonephritis, Membranoproliferative (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Lupus Erythematosus, Systemic (2) · Adenine phosphoribosyltransferase deficiency (1)
Autoimmune Diseases (47) · Female Urogenital Diseases (47) · Female Urogenital Diseases and Pregnancy Complications (47) · Immune System Diseases (47) · Male Urogenital Diseases (47) · Urogenital Diseases (47) · Nephritis (46) · Urologic Diseases (46) · Kidney Diseases (43) · Glomerulonephritis (42) · Nephrosis (15) · Skin and Connective Tissue Diseases (11) · Connective Tissue Diseases (10) · Pathological Conditions, Signs and Symptoms (9) · Lupus Erythematosus, Systemic (6)
Rituximab (7) · Blood Specimen Collection (2) · felzartamab (2) · obinutuzumab (2) · Adrenal Cortex Hormones (1) · Adrenocorticotropic Hormone (1) · Amoxicillin (1) · Clarithromycin (1) · Cyclophosphamide (1) · Cyclosporine (1) · Interferon-alpha (1) · Interviews as Topic (1) · Lansoprazole (1) · Methylprednisolone (1) · N-acetylmannosamine (1)
Mario Negri Institute for Pharmacological Research (6) · Centre Hospitalier Universitaire de Nice (5) · University of Michigan (3) · Assistance Publique - Hôpitaux de Paris (2) · Istanbul University (2) · Mayo Clinic (2) · Air Force Military Medical University, China (1) · Alpine Immune Sciences, Inc. (1) · Apellis Pharmaceuticals, Inc. (1) · Assiut University (1) · Axiom Bioregistry (1) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · BioCryst Pharmaceuticals (1) · Chinese University of Hong Kong (1) · Grit Biotechnology (1)
United States (13) · China (8) · France (8) · Italy (7) · South Korea (3) · United Kingdom (3) · Greece (2) · Spain (2) · Turkey (Türkiye) (2) · Australia (1) · Canada (1) · Georgia (1) · Germany (1) · Hong Kong (1) · Jordan (1)
Fernando C. Fervenza, M.D., Ph.D. (2) · Giuseppe Remuzzi, M.D. (2) · Giuseppe Remuzzi, MD (2) · Matthias Kretzler, MD (2) · Barbara Seitz-polski (1) · Berna Yelken, MD (1) · Carla M Nester, MD, MSA, FASN (1) · Carla Nester, MD (1) · Daniel Crona, PharmD, PhD (1)
PMID 34778952, PMID 24707402, PMID 26577187, PMID 26589142, PMID 31340979, PMID 32842999, PMID 33311560, PMID 34060483, PMID 34721403, PMID 34796395, PMID 36283759, PMID 37036696, PMID 39899371, PMID 40180405, PMID 40465397, PMID 41630898, PMID 42027554
R01DK141114 (2), U54DK083912 (2)